



PRESS INFORMATION

Pneumococcal Vaccines Accelerated Development and Introduction Plan (PneumoADIP)

Pneumonia and meningitis

More children die each year from pneumonia than from any other infectious disease – even more than malaria or AIDS. Nearly all of these deaths occur in the world's poorest countries. WHO estimates that pneumonia caused 800 000 to 1 million deaths in children in 2000 and most of those deaths are believed to be due to bacterial pneumonia. Bacterial meningitis is one of the most fatal illnesses of childhood, killing or disabling 40 to 75% of the children who get it.

Streptococcus pneumoniae, also known as pneumococcus

Pneumococcus is the most common cause of bacterial pneumonia in infants and young children and the most severe cause of bacterial meningitis. In studies of patients with pneumonia, *S. pneumoniae* is consistently the most commonly identified bacterium found in either lung aspirates or blood cultures. Underlying illnesses such as HIV infection and malnutrition only worsen the situation. In South Africa, HIV positive children have a 20 to 40 fold increased risk of getting pneumococcal pneumonia. The HIV epidemic will create an enormous increase in pneumonia cases in developing countries in the years to come.

Vaccines

Vaccines are currently available to prevent pneumococcal disease. However, without a coordinated effort by GAVI's PneumoADIP, past experiences have shown that it will take 20 years or more, for these vaccines to reach 25 % of the children in developing countries. Pneumococcal vaccination is needed urgently and if accelerated, routine vaccination in developing countries between 2010 and 2015 could significantly contribute to achieving the United Nations' Millennium

Development Goal #4: To decrease the child mortality rate by two-thirds by the year 2015.


The PneumoADIP Mission

The PneumoADIP mission is to improve child survival and health by accelerating the evaluation of and access to, new life saving pneumococcal vaccines for the world's poorest children. The PneumoADIP aims to achieve its mission by reducing and sharing risks with the private sector and in return obtaining a more sustainable, affordable supply of vaccine for developing countries. An effective and successful PneumoADIP could lead to millions of lives saved through earlier and faster access to vaccines.

The ADIP Approach

The PneumoADIP team is a small dedicated team based at Johns Hopkins Bloomberg School of Public Health and supported by \$30,000,000 from the Global Alliance for Vaccines and Immunization and its partner, the Vaccine Fund. The PneumoADIP is organized around three main areas of activities.

- 1.** Establishing the value of vaccination by demonstrating the burden of meningitis and pneumonia caused by pneumococcal bacteria and demonstrate the value of preventing it through vaccination.
- 2.** Communicating effectively to key decision makers the knowledge about disease burden and the value of vaccination by assuring that research data are communicated through appropriate and effective communication channels.
- 3.** Delivering the value of the vaccine by assuring that there is a predictable supply of quality vaccine at an affordable price, an adequate system to deliver it to the children who need it, and the financing to sustain its use.



Please visit: <http://www.preventpneumo.org>

* * * * *

For further information, please contact:

Hans Kvist
 Director of Communications
 PneumoADIP, on-site at Helsinki

Mobile: +1 410 736 8243
 Email: hkvist@luvix.com